Summary
Medtronic plc reported financial results for the three months ended July 29, 2016, showing a slight decrease in net sales to $7.17 billion from $7.27 billion in the prior year's comparable quarter. Despite the marginal dip in revenue, the company demonstrated improved profitability, with net income rising by 13% to $929 million, and diluted earnings per share increasing by 16% to $0.66 from $0.57. This improved profitability was largely driven by a decrease in the cost of products sold, partly due to the amortization of inventory fair value adjustments from the Covidien acquisition, and a significant reduction in the effective tax rate from 12.8% to 6.0%, aided by favorable tax adjustments and resolution of certain tax issues. The company highlighted strategic acquisitions, including HeartWare International for $1.1 billion and Smith & Nephew's gynecology business for $350 million, which are expected to bolster its offerings in heart failure and minimally invasive surgical products, respectively. Medtronic also continued its focus on cost synergies from the Covidien integration and is on track to achieve its targets. While overall sales saw a modest decline, driven by factors like an extra selling week in the prior year's comparable period and currency headwinds, several product lines within the Cardiac and Vascular Group and the Diabetes Group showed positive growth. The company's financial health remains robust, with significant operating cash flow and a healthy liquidity position.
Financial Highlights
52 data points| Revenue | $7.17B |
| Cost of Revenue | $2.26B |
| Gross Profit | $4.91B |
| SG&A Expenses | $2.43B |
| Operating Income | $1.17B |
| Interest Expense | $272.00M |
| Net Income | $929.00M |
| EPS (Basic) | $0.67 |
| EPS (Diluted) | $0.66 |
| Shares Outstanding (Basic) | 1.39B |
| Shares Outstanding (Diluted) | 1.41B |
Key Highlights
- 1Net sales for the quarter were $7.17 billion, a decrease of 1% compared to the prior year's $7.27 billion, impacted by an extra selling week in the prior year's comparable period and currency headwinds.
- 2Net income increased by 13% to $929 million, and diluted earnings per share (EPS) rose by 16% to $0.66, demonstrating improved profitability.
- 3The effective tax rate significantly decreased to 6.0% from 12.8% in the prior year, primarily due to favorable tax adjustments and resolution of certain tax issues.
- 4Significant strategic acquisitions were announced, including HeartWare International for approximately $1.1 billion and Smith & Nephew's gynecology business for approximately $350 million, aimed at strengthening specific business segments.
- 5Operating cash flow was strong at $1.55 billion, and free cash flow was $1.22 billion, underscoring robust cash generation.
- 6Cost of products sold decreased as a percentage of net sales, partly due to the amortization of the Covidien inventory fair value adjustment.
- 7The company continues to execute on cost synergies from the Covidien acquisition, with approximately $850 million expected to be achieved through fiscal year 2018.